JP6972002B2 - ブルトン型チロシンキナーゼを調節する化合物及び方法 - Google Patents

ブルトン型チロシンキナーゼを調節する化合物及び方法 Download PDF

Info

Publication number
JP6972002B2
JP6972002B2 JP2018547964A JP2018547964A JP6972002B2 JP 6972002 B2 JP6972002 B2 JP 6972002B2 JP 2018547964 A JP2018547964 A JP 2018547964A JP 2018547964 A JP2018547964 A JP 2018547964A JP 6972002 B2 JP6972002 B2 JP 6972002B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
independently
alkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018547964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507793A5 (https=
JP2019507793A (ja
Inventor
ハドソン，ライアン
ボーソレイユ，アン−マリー
ミラー，リチャード・エイ
バーナー，エリック
Original Assignee
エンジェル・ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンジェル・ファーマシューティカル・カンパニー・リミテッド filed Critical エンジェル・ファーマシューティカル・カンパニー・リミテッド
Publication of JP2019507793A publication Critical patent/JP2019507793A/ja
Publication of JP2019507793A5 publication Critical patent/JP2019507793A5/ja
Application granted granted Critical
Publication of JP6972002B2 publication Critical patent/JP6972002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2018547964A 2016-03-11 2017-03-10 ブルトン型チロシンキナーゼを調節する化合物及び方法 Active JP6972002B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2019507793A JP2019507793A (ja) 2019-03-22
JP2019507793A5 JP2019507793A5 (https=) 2020-05-14
JP6972002B2 true JP6972002B2 (ja) 2021-11-24

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547964A Active JP6972002B2 (ja) 2016-03-11 2017-03-10 ブルトン型チロシンキナーゼを調節する化合物及び方法

Country Status (12)

Country Link
US (2) US10870652B2 (https=)
EP (1) EP3426637B1 (https=)
JP (1) JP6972002B2 (https=)
KR (1) KR102416971B1 (https=)
CN (2) CN109071455B (https=)
AU (1) AU2017230098B2 (https=)
ES (1) ES2912465T3 (https=)
IL (1) IL261583A (https=)
MX (1) MX388026B (https=)
PL (1) PL3426637T3 (https=)
WO (1) WO2017156495A1 (https=)
ZA (1) ZA201805951B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071455B (zh) * 2016-03-11 2022-08-02 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
WO2018175512A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
CN113544130B (zh) 2019-05-31 2024-01-09 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
FI4036095T3 (fi) * 2019-09-26 2024-02-14 Jumbo Drug Bank Co Ltd 4-Fluori-1H-pyratsolo[3,4-c]pyridiinijohdannaisia selektiivisinä Brutonin tyrosiinikinaasin (BTK) inhibiittoreina B-solulymfooman ja autoimmuunitautien hoitamiseksi
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
CN117377675A (zh) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
TW202321191A (zh) * 2021-07-29 2023-06-01 美商賽迪拉治療股份有限公司 Ｔｅａｄ抑制劑及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW502019B (en) * 1999-03-26 2002-09-11 Cocensys Inc Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
KR101417136B1 (ko) * 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
WO2007095223A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20120101114A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8633318B2 (en) 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
JP2014520863A (ja) * 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP2016538270A (ja) 2013-10-25 2016-12-08 ファーマサイクリックス エルエルシー 移植片対宿主病を処置し予防する方法
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP3414234B1 (en) * 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102699906B1 (ko) * 2016-01-21 2024-08-29 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 브루톤 티로신 키나제 억제제
CN109071455B (zh) * 2016-03-11 2022-08-02 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法

Also Published As

Publication number Publication date
ZA201805951B (en) 2020-12-23
MX2018010971A (es) 2019-03-28
CA3017567A1 (en) 2017-09-14
KR20180133415A (ko) 2018-12-14
AU2017230098B2 (en) 2021-03-25
CN115746000A (zh) 2023-03-07
WO2017156495A8 (en) 2018-09-27
ES2912465T3 (es) 2022-05-26
EP3426637A4 (en) 2019-09-18
US20190106423A1 (en) 2019-04-11
EP3426637B1 (en) 2022-02-09
US10870652B2 (en) 2020-12-22
MX388026B (es) 2025-03-19
US11306099B1 (en) 2022-04-19
WO2017156495A1 (en) 2017-09-14
NZ745927A (en) 2024-05-31
KR102416971B1 (ko) 2022-07-04
CN109071455B (zh) 2022-08-02
AU2017230098A1 (en) 2018-09-20
EP3426637A1 (en) 2019-01-16
CN109071455A (zh) 2018-12-21
PL3426637T3 (pl) 2022-05-30
IL261583A (en) 2018-10-31
JP2019507793A (ja) 2019-03-22

Similar Documents

Publication Publication Date Title
JP6972002B2 (ja) ブルトン型チロシンキナーゼを調節する化合物及び方法
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
JP7236996B2 (ja) インターロイキン－２誘導性ｔ細胞キナーゼを調節する化合物及び方法
ES2296667T3 (es) Inhibidores basados en pirazina de glicogeno sintasa quinasa-3.
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CN116490184B (zh) 用于抑制egfr突变癌症的化合物及其药物用途
WO2017044889A1 (en) Lrh-1 modulators
JP2015532287A (ja) Ｉｒｅ１の調節
CN108430978B (zh) 3-羟基-喹唑啉-2,4-二酮衍生物及其作为核酸酶调节剂的用途
US20240383900A1 (en) Substituted pyrazolo [1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
TW202421130A (zh) 作為pi3k抑制劑的異喹啉酮
JP2019514869A (ja) ＥｒｂＢ阻害剤及びその使用
JP2018534243A (ja) アンドロゲン受容体拮抗薬
KR20220159346A (ko) 카스파제 6 억제제 및 이의 용도
KR20240119138A (ko) 피리미딘 또는 피리딘 유도체 및 이의 의약적 용도
WO2021061053A1 (en) Therapeutic compounds and methods of use thereof
WO2020198067A1 (en) Pkm2 modulators and methods for their use
JP7088912B2 (ja) ジチオｅｔｐ誘導体
CN114127070A (zh) 具有a2a腺苷受体激动剂活性的6-肼基腺苷类化合物
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2026012504A1 (zh) 用于降解目标蛋白的crbn结合化合物及其应用
HK40009984A (en) Erbb inhibitors and uses thereof
HK40080873A (en) 3, 4 - dihydroisoquinoline compound and use thereof
CN113735825A (zh) 1,2,3,6-四氢吡啶类化合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

R150 Certificate of patent or registration of utility model

Ref document number: 6972002

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250